Physician

Nehad Soloman, M.D.

According to 2025 Medicare claims, Nehad Soloman, M.D. (NPI: 1356302962) practices rheumatology in the Phoenix-Mesa-Chandler, AZ market, with the plurality of this provider's patient population coming from Maricopa, AZ. This provider's primary affiliated billing organization is ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES P C (NPI: 1366489254; TIN: 860765242) and primary practice location at 85351-2748.

Soloman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,268 traditional Medicare patients, billed 561,273 HCPCS/CPT codes, and received $7,698,241 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,640 prescription claims across 614 beneficiaries totaling $4,364,934 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 486 records totaling $825,984. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,131,211 to $7,698,241. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,597,009 to $4,364,934. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	679	81,550	$1,131,211
2016	796	118,484	$1,647,155
2017	869	145,933	$2,311,279
2018	929	177,815	$3,029,935
2019	1,069	236,510	$3,921,935
2020	1,059	336,731	$5,427,216
2021	1,040	304,462	$6,182,221
2022	1,202	359,992	$6,673,370
2023	1,324	512,482	$7,323,053
2024	1,268	561,273	$7,698,241

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	508	3,437	$1,597,009
2016	516	3,385	$1,626,175
2017	657	3,863	$1,475,877
2018	674	3,853	$1,820,687
2019	665	3,844	$2,640,266
2020	726	3,981	$2,086,447
2021	702	3,702	$3,094,000
2022	679	3,250	$3,676,969
2023	611	2,795	$4,759,968
2024	614	2,640	$4,364,934

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	953	2,174	$97
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	647	1,220	$13
80053	Blood test, comprehensive group of blood chemicals	799	1,722	$10
36415	Insertion of needle into vein for collection of blood sample	839	1,991	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	594	1,367	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	109	3,404	$851,042
Xeljanz Xr	Tofacitinib Citrate	66	2,160	$412,596
Enbrel Sureclick	Etanercept	47	1,428	$384,471
Rinvoq	Upadacitinib	39	1,170	$263,839
Otezla	Apremilast	47	1,470	$223,475

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	435	$193,287	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	51	$632,697	Amgen Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Nehad Soloman, M.D.?

Tedicare shows public-source Medicare data for Nehad Soloman, M.D. (NPI 1356302962), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Nehad Soloman, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Nehad Soloman, M.D.?

Nehad Soloman, M.D. is linked to ARIZONA ARTHRITIS & RHEUMATOLOGY ASSOCIATES P C (billing NPI 1366489254) in the available physician profile data.

Does Nehad Soloman, M.D. have Open Payments data?

Nehad Soloman, M.D. has 486 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.